Cold-Promoted Activation of Factor VII and Shortening of the Prothrombin Time

  • Harvey R. Gralnick
  • Olga J. Wilson


The previous speakers have summarized our knowledge concerning the biochemistry, function, synthesis and molecular biology of the coagulation factors II, VII, IX, X, and protein C and S. In particular, they have highlighted the role of the gamma carboxyglutamic acid, the biosynthetic rates and the specific steps in the activation of these proteins. This has led to a clear understanding of the biologic effect of the vitamin K antagonists. The studies of tissue factor have elucidated various aspects of this apoprotein and its function. Yet with this great body of knowledge, there is still a great deal of consternation about the test most commonly utilized to clinically monitor the effects of vitamin K antagonists, the prothrombin time.


Prothrombin Time Oral Anticoagulant Therapy Plasma Kallikrein High Molecular Weight Kininogen Hageman Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    National Committee for Clinical Laboratory Standards. Collection, transport and preparation of blood specimens for coagulation testing and performance of coagulation assays; Approved Guideline. NCCLS Document H21-A, Villanova, PA: NCCLS, (1986).Google Scholar
  2. 2.
    National Committee for Clinical Laboratory Standards. Proposed guidelines for the one-stage prothrombin time test (PT). NCCLS Document H28-P 2:362–380, Villanova, PA: NCCLS (1982).Google Scholar
  3. 3.
    R.N. Palmer, CM. Kessler, and H.R. Gralnick, Warfarin anticoagulation: Difficulties in interpretation of the prothrombin time, Thromb. Res. 25:125 (1982).PubMedCrossRefGoogle Scholar
  4. 4.
    A.M.H.P. van den Besselaar and E.A. Loeliger, The effect of contact activation on the prothrombin time with special reference to theuse of evacuated tubes, in: “Standardization of Coagulation Assays: An Overview,” D.A. Triplett, ed., College of American Pathologists, Skokie, IL (1982).Google Scholar
  5. 5.
    H.R. Gralnick, C.R. Kessler, and R. Palmer, The prothrombin time: Variables affecting results, in: “Standardization of Coagulation Assays: An Overview,” D.A. Triplett, ed., College of American Pathologists, Skokie, IL (1982).Google Scholar
  6. 6.
    R.N. Palmer and H.R. Gralnick, Inhibition of cold-promoted activation of the prothrombin time studies of new siliconized borosilicate collection tubes in normals and patients receiving warfarin, Am. J. Clin. Path. 83:492 (1985).PubMedGoogle Scholar
  7. 7.
    J.A. Thomson, “Blood Coagulation and Haemostasis: A Practical Guide,” Churchill Livingstone, London (1985).Google Scholar
  8. 8.
    A.M.H.P. van den Besselaar, L.P. van Halem-Visser, and E.A. Loeliger, The use of evacuated tubes for blood collection in oral anticoagulant control, Thromb. Haemost. 50:676 (1983).PubMedGoogle Scholar
  9. 9.
    K. Lenggenhager, quoted in: “The Coagulation of Blood: Investigations on a New Clotting Factor,” P.A. Owren, ed., J. Chr. Gundersen, Oslo, p 53 (1947).Google Scholar
  10. 10.
    B. Alexander, A. DeVries, and R. Goldstein, A factor in serum which accelerated the conversion of prothrombin to thrombin. II. Its evaluation with special reference to the influence of conditions which affect blood coagulation, Blood 4:739 (1949).PubMedGoogle Scholar
  11. 11.
    S.I. Rapaport, K Aas, and P.A. Owren, The effect of glass upon the activity of the various plasma clotting factors,J. Clin. Invest. 34:9 (1954).CrossRefGoogle Scholar
  12. 12.
    O.D. Ratnoff and J.E. Colopy, A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. Clin. Invest. 34:102 (1955).CrossRefGoogle Scholar
  13. 13.
    O.D. Ratnoff and J.M. Rosenblum, Role of Hageman factor in the initiation of clotting by glass: Evidence that glass frees Hageman factor from inhibition, Am. J. Med. 25:160 (1958).PubMedCrossRefGoogle Scholar
  14. 14.
    H. Gjonnaess, Cold promoted activation of factor VII. I. Evidence for the existence of an activator, Thromb. Diath. Haemorrh. 28:155 (1972).PubMedGoogle Scholar
  15. 15.
    H. Gjonnaess, Cold promoted activation of factor VII. II. Identification of the activator, Thromb. Diathes. Haemorrh. 28:169 (1972).Google Scholar
  16. 16.
    H. Gjonnaess, Cold promoted activation of factor VII. III. Relation to the kallikrein system, Thromb. Diath. Haemorrh. 28:182 (1972).PubMedGoogle Scholar
  17. 17.
    R.N. Palmer and H.R. Gralnick, Cold-induced contact surface activation of the prothrombin time in whole blood, Blood 59:38 (1982).PubMedGoogle Scholar
  18. 18.
    R. Radcliffe, A. Bagdasarian, R. Colman, and Y. Nemerson, Activation of bovein factor VII by Hageman factor fragments, Blood 50:611 (1977).PubMedGoogle Scholar
  19. 19.
    W. Kisiel, K. Fujikawa, and E.W. Davie, Activation of bovine factor VII (proconvertin) by factor Xlla (activated Hageman factor), Biochemistry 16:4189 (1977).PubMedCrossRefGoogle Scholar
  20. 20.
    K. Laake and B. Osterud, Activation of purified plasma factor VII by human plasmin, plasma kallikrein and activated components of the human intrinsic blood coagulation system, Thromb. Res. 5:759 (1974).PubMedCrossRefGoogle Scholar
  21. 21.
    U. Seligsohn, B. Sterud, F. Brown, J.H. Griffin, and S.I. Rapaport, Activation of human factor VII in plasma and in purified systems, J. Clin. Invest. 64:1056 (1979).PubMedCrossRefGoogle Scholar
  22. 22.
    U. Seligsohn, B. Osterud, J. Griffin, and S.I. Rapaport, Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activaiton of factor VII, Thromb. Res. 13:1049 (1978).PubMedCrossRefGoogle Scholar
  23. 23.
    H. Gjonnaess, Cold promoted activation of factor VII. IV. Relation to the coagulation system, Thromb. Diath. Haemorrh. 28:194 (1972).PubMedGoogle Scholar
  24. 24.
    H. Saito and O. Ratnoff, Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): A potential link between the intrinsic and extrinsic blood clotting system, J. Lab. Clin. Med. 85:405 (1975).PubMedGoogle Scholar
  25. 25.
    G.J. Miller, M.J. Seghatchian, S.J. Walter, D.J. Howarth, S.G. Thompson, M.P. Esnouf, and T.W. Meade, An association between the factor VII coagulant activity and thrombin activity induced by surface/cold exposure of normal human plasma, Brit. J. Haematol. 62:379 (1986).CrossRefGoogle Scholar
  26. 26.
    A.D. Muller, W.A. van Deijk, P.P. Devilee, M.S.C. van Dam-Mieras, and H.C. Hemker, The activity state of factor VII in plasma: two pathways for the cold promoted activation of factor VII, Brit. J. Haematol. 62:367 (1986).CrossRefGoogle Scholar
  27. 27.
    C. Cochrane and J. Griffin, Molecular assembly in the contact phase of Hageman factor system, Am. J. Med. 67:657 (1979).PubMedCrossRefGoogle Scholar
  28. 28.
    A. Kaplan, The Hageman factor dependent pathways of human plasma, Microvasc. Res. 8:97 (1974).PubMedCrossRefGoogle Scholar
  29. 29.
    M. Zur and Y. Nemerson, Kinetics of factor IX activation via the extrinsic pathway: dependence of Km on tissue factor, J. Biol. Chem. 255:5703 (1980).PubMedGoogle Scholar
  30. 30.
    E.A. van Royen, S. Lohman, M. Voss, and K.W. Pondman, C1 inactivator and cold-promoted activation of factor VII, J. Lab. Clin. Med. 92:152 (1978).PubMedGoogle Scholar
  31. 31.
    O.D. Ratnoff, J. Pensky, D. Ogston, and G. Naff, The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C’lr subcomponent inhibitor, J. Exp. Med. 129:315 (1969).PubMedCrossRefGoogle Scholar
  32. 32.
    B. Bouma, D. Kerbiriou, R. Vlooswijk, and J. Griffin, Immunological studies of perkallikrein, kallikrein and high-molecular-weight kininogen in normal and deficient plasmas and in normal plasma after cold-promoted activation. J. Lab. Clin. Med. 96:693 (1980).PubMedGoogle Scholar
  33. 33.
    R. Weiss, M. Silverberg, and A.P. Kaplan, The effect of C1 inhibitor upon Hageman factor autoactivation, Blood 68:239 (1986).PubMedGoogle Scholar
  34. 34.
    E.M. Gordon, O.D. Ratnoff, H. Saito, V.H. Donaldson, J. Pensky and P.K. Jones, Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives, J. Lab. Clin. Med. 96:762 (1980).PubMedGoogle Scholar
  35. 35.
    C Czendlik, B. Lammie, and F. Duckert, Cold promoted activation and factor XII, prekallikrein and C1-inhibitor, Thromb. Haemost. 53:242 (1985).PubMedGoogle Scholar
  36. 36.
    Y. Hojima, J.V. Pierce, and J.J. Pisano, Hageman factor fragment inhibitor in corn seeds: purification and characterization, Thromb. Res. 20:149 (1980).PubMedCrossRefGoogle Scholar
  37. 37.
    E. Marks, Y. Hojima, M.E. Frech, H. Keiser, and J.J. Pisano, An inhibitor form corn blocks the hypotensive action of plasma protein fraction and active Hageman factor, Thromb. Res. 23:97 (1981).PubMedCrossRefGoogle Scholar
  38. 38.
    R.N. Palmer, and H.R. Gralnick, Inhibition of the cold activation of factor VII and the prothrombin time, Am. J. Clin. Path. 81:618 (1984).PubMedGoogle Scholar
  39. 39.
    H. Nossel, H. Rubin, M. Drillings, and R. Hsieh, Inhibition of Hageman factor activation, J. Clin. Invest. 47:1172 (1968).PubMedCrossRefGoogle Scholar
  40. 40.
    U. Seligsohn, B. Osterud, and S.I. Rapaport, Coupled amidolytic assay for factor VII: Its use with a clotting assay to determine the activity state of factor VII, Blood 52:978 (1978).PubMedGoogle Scholar
  41. 41.
    G. Avvisati, J.W. Ten Cate, E.M. van Wijk, L.H. Kahle, and G. Mariani, Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment, Brit. J. Haematol. 45:343 (1980).CrossRefGoogle Scholar
  42. 42.
    R.A. Blanchard, B.C. Furie, S.F. Kruger, G. Waneck, M.J. Jorgensen, and B. Furie, Immunoassays of human prothrombin species which correlate with functional coagulant activities. J. Lab. Clin. Med. 101:242 (1983).PubMedGoogle Scholar
  43. 43.
    B. Furie, H.A. Liebman, R.A. Blanchard, M.S. Coleman, S.F. Kruger, and B.C. Furie, Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy, Blood 64:445 (1984).PubMedGoogle Scholar
  44. 44.
    D.J. Howarth, M. Brozovic, Y. Stirling, and M. Reed, Factor VII during warfarin treatment, Scand. J. Haematol. 12:346 (1974).PubMedCrossRefGoogle Scholar
  45. 45.
    D.S. Fair, Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay, Blood 62:784 (1983).PubMedGoogle Scholar
  46. 46.
    A.R. Thompson, Factor IX antigen by radioimmunoassay: Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B, J. Clin. Invest. 59:900 (1977).PubMedCrossRefGoogle Scholar
  47. 47.
    K.H. Orstavik, and K. Laake, Factor IX in warfarin treated patients, Thromb. Res. 13:207 (1978).PubMedCrossRefGoogle Scholar
  48. 48.
    D.S. Fair, and T.S. Edgington, Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses, Brit. J. Haematol. 59:235 (1985).CrossRefGoogle Scholar
  49. 49.
    B. Osterud, How to measure factor VII and factor VII activation, Haemostasis 13:161 (1983).PubMedGoogle Scholar
  50. 50.
    W.A. van Deijk, M.C.E. van Dam-Mieras, A.D. Muller and H.C. Hemker, Evaluation of a coagulation assay determining the activity state of factor VII in plasma, Haemostasis 13:192 (1983).PubMedGoogle Scholar
  51. 51.
    T.W. Meade, R. Chakrabarti, A.P. Haines, W.R.S. North, Y. Stirling, S.G. Thompson, and M. Brozovic, Haemostatic function and cardiovascular death: Early results of a prospective study, Lancet, May 17:1050 (1980).CrossRefGoogle Scholar
  52. 52.
    T.W. Meade, A.P. Haines, J.D. Imeson, Y. Stirling, and S.G. Thompson, Menopausal status and haemostatic variables, Lancet i:22 (1983).CrossRefGoogle Scholar
  53. 53.
    G.J. Miller, S.J. Walter, Y. Stirling, S.G. Thompson, M.P. Esnouf, and T.W. Meade, Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha-Vila in hyperlipidaemia, with possible implications for ischaemic heart disease, Brit. J. Haematol. 59:249 (1985).CrossRefGoogle Scholar
  54. 54.
    A.C.A. Carvalho, R.S. Lees, R.A. Vaillancourt, R.B. Cabrai, and R.W. Colman, Activation of the kallikrein system in hyperbetalipoproteinemia, J. Lab. Clin. Med. 91:117 (1978).PubMedGoogle Scholar
  55. 55.
    K. Dalaker, I. Hjermann, and H. Prydz, A novel form of factor VII in plasma from men at risk for cardiovascular disease, Brit. J. Haematol. 61:315 (1985).CrossRefGoogle Scholar
  56. 56.
    T.W. Meade, Factor VII and ischaemic heart disease: Epidemiological evidence, Haemostasis 13:178 (1983).PubMedGoogle Scholar
  57. 57.
    W.A. van Deijk, M.C.E. van Dam-Mieras, and A.D. Muller, Activation of factor VII in patients with carcinoma of the prostate: A preliminary report, Haemostasis 13:198 (1983).PubMedGoogle Scholar
  58. 58.
    K. Dalaker, and H. Prydz, The coagulation factor VII in pregnancy, Brit. J. Haematol. 56:233 (1984).CrossRefGoogle Scholar
  59. 59.
    T.W. Meade, M. Brozovic, R. Chakrabarti, D.J. Howarth, W.R.S. North, and Y. Stirling, An epidemiological study of the haemostatic and other effect of oral contraceptive, Brit. J. Haematol. 34:353 (1976).CrossRefGoogle Scholar
  60. 60.
    E.M. Gordon, O.D. Ratnoff, and P.K. Jones, The role of augmented Hageman factor (factor XII) titers in the cold-promoted activition of factor VII and spontaneous shortening of the prothrombin time in women using oral contraceptives, J. Lab. Clin. Med. 99:363 (1982).PubMedGoogle Scholar
  61. 61.
    U. Seligsohn, A. Zivelin, and S. Bar-Shani, Cold-promoted activation of factor VII: Is it a problem under blood bank conditions? Haemostasis 13:186 (1983).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Harvey R. Gralnick
    • 1
  • Olga J. Wilson
    • 1
  1. 1.Hematology Service, Clinical Pathology Department, Clinical CenterNational Institutes of HealthBethesdaUSA

Personalised recommendations